THERAPY DOSSIER · th-fc70a059f136

Dihydrodiosgenin (Dydio), a spiroacetal ring-opened analogue of diosgenin

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06639698 ↗NAcompleted

Diosgenin, vitamin D and alpha-lactalbumin supplementation for menstrual cycle alterations in PCOS phenotype D

PCOS (Polycystic Ovary Syndrome)

Enrolment: 24 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29457828 ↗2018Reported benefit

Dihydrodiosgenin protects against experimental acute pancreatitis and associated lung injury through mitochondrial protection and PI3Kgamma/Akt inhibition.

MixedChemical/toxinWistar rats; BALB/c miceMale5 or 10 mg/kgAdministered after induction of acute pancreatitis (therapeutic administration)

Model: Three models of acute pancreatitis with associated acute lung injury: sodium taurocholate-induced acute pancreatitis in Wistar rats, caerulein-induced acute pancreatitis and palmitoleic acid plus ethanol-induced acute pancreatitis in BALB/c mice

Therapeutic dihydrodiosgenin reduced acinar necrosis and mitochondrial dysfunction, improved biochemical and histopathological indices in all three acute pancreatitis models via mitochondrial protection and PI3Kgamma/Akt inactivation, and lessened associated acute lung injury.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…